Diagonal Therapeutics: Funding, Investors & Team (Oct 2026)
Diagonal Therapeutics is a biotechnology company that develops targeted therapies for cancer by integrating molecular biology, genomic data, and translational research to identify and advance precision oncology drug candidates. Its platform focuses on genetically defined cancer dependencies and novel mechanisms of action to create small molecule and biologic therapies that aim to disrupt key pathways driving tumor growth and survival. The company’s research approach combines target discovery, medicinal chemistry, and preclinical validation to progress programs toward clinical evaluation with the goal of addressing unmet needs in oncology. Diagonal Therapeutics also collaborates with academic partners and leverages external datasets to inform its therapeutic strategies and enhance predictive models for treatment response. Its pipeline includes programs across multiple cancer types that are designed to exploit specific genetic or phenotypic vulnerabilities in tumor cells.
Diagonal Therapeutics has raised $125M across 1 funding round on record, the most recent a Series B of $125M announced in Jan 2026.
That round is above the $8.1M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Diagonal Therapeutics Company Profile and Key Stats
Latest funding round on record: Jan 2026.
Diagonal Therapeutics Funding Rounds
Diagonal Therapeutics Founders and Leadership Team
No contact details are on record for this team yet.
Diagonal Therapeutics Funding Compared to Other Biotechnology Startups
Diagonal Therapeutics' latest round of $125M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Diagonal Therapeutics in Biotechnology and Watertown
Companies Similar to Diagonal Therapeutics
Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the…
Astrocyte Pharmaceuticals is a drug development company that helps in the recovery and well-being of brain…
Tiny Health offers a gut health test specifically designed for mothers and babies aged 0 to 3 years.…
Junevity is dedicated to using cutting-edge transcription factor medicines to combat age-related diseases.…
Arkea Bio creates technology aimed at reducing greenhouse gas (GHG) emissions in the agricultural sector.
Serán is a contract development and manufacturing organization providing a comprehensive suite of…
Precision’s goal is to provide breakthrough treatments for the one billion patients worldwide suffering from…
Enveda is a biotechnology company that utilizes AI-powered tools to explore and characterize molecules from…
Avery Therapeutics, Inc. is a company dedicated to developing tissue engineered therapeutics to treat…
Circle Pharma is a biotechnology company in the initial stages of development that uses unique computational…
Evvy is for people with vaginas who want to be empowered with information about their microbiome. Their…
Diagonal Therapeutics Funding FAQs
What does Diagonal Therapeutics do?
Diagonal Therapeutics is a biotechnology company that develops targeted therapies for cancer by integrating molecular biology, genomic data, and translational research to identify and advance precision oncology drug candidates. Its platform focuses on genetically defined cancer dependencies and novel mechanisms of action to create small molecule and biologic therapies that aim to disrupt key pathways driving tumor growth and survival. The company’s research approach combines target discovery, medicinal chemistry, and preclinical validation to progress programs toward clinical evaluation with the goal of addressing unmet needs in oncology. Diagonal Therapeutics also collaborates with academic partners and leverages external datasets to inform its therapeutic strategies and enhance predictive models for treatment response. Its pipeline includes programs across multiple cancer types that are designed to exploit specific genetic or phenotypic vulnerabilities in tumor cells.
How much funding has Diagonal Therapeutics raised?
Diagonal Therapeutics has raised $125M across 1 round on record. The most recent is a Series B of $125M announced in Jan 2026.
When did Diagonal Therapeutics last raise funding?
Diagonal Therapeutics' most recent funding round on record is a Series B of $125M, announced in Jan 2026.
Who founded Diagonal Therapeutics?
FundedIQ lists Alexey Lugovskoy (Founder) at Diagonal Therapeutics.
Where is Diagonal Therapeutics headquartered?
Diagonal Therapeutics is based in Watertown, Massachusetts, United States.
How many employees does Diagonal Therapeutics have?
Diagonal Therapeutics is in the 11-50 employee band.
How does Diagonal Therapeutics' funding compare to other Biotechnology startups?
Diagonal Therapeutics' latest round of $125M is above the $8.1M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's Diagonal Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Diagonal Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.